Cargando…
Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most often found in the gastrointestinal system or the pancreas. However, patient-reported health state utilities based on clinical trials have not been previously reported in this disease area. METHODS: The CLARIN...
Autores principales: | Meng, Yang, McCarthy, Grant, Berthon, Anthony, Dinet, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492941/ https://www.ncbi.nlm.nih.gov/pubmed/28662673 http://dx.doi.org/10.1186/s12955-017-0711-z |
Ejemplares similares
-
Cost‐of‐illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden—A population‐based register‐linkage study
por: Lesén, Eva, et al.
Publicado: (2019) -
Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study
por: Lesén, Eva, et al.
Publicado: (2019) -
Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
por: Jalbert, Jessica J., et al.
Publicado: (2020) -
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013) -
Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours
por: Clement, Dominique S. V. M., et al.
Publicado: (2023)